USPTO serial 79160465
PETIZATION
Reviewed by CopyMark Law Group
Reg. 4879066Status 404
- Filing date
- Status date
- Registration date
- Jan 5, 2016
- Examiner
- GLASSER, CARYN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with PETIZATION?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Biological preparations for pharmaceutical purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; pharmaceutical preparations for the treatment of pain, itch, diabetes, cancer, and inflammation; pharmaceutical preparations for animals for the treatment of pain, itch, diabetes, cancer, and inflammation; pharmaceutical preparations for veterinary use for the treatment of pain, itch, diabetes, cancer, and inflammation; radioactive preparations for veterinary use for the treatment of pain, itch, diabetes, cancer, and inflammation; reagents for in-vitro laboratory use for medical diagnostic veterinary purposes; reagents for laboratory purposes for medical diagnostic veterinary purposes; reagents for use in analytical tests for medical diagnostic veterinary purposes; reagents for use in diagnostic tests for medical diagnostic veterinary purposes; reagents for use in the development of monoclonal antibodies for medical diagnostic veterinary purposes; reagents in kit form for conducting enzyme-linked immunosorbent assays (ELISA) for medical diagnostic veterinary purposes; veterinary preparations for the treatment of pain, itch, diabetes, cancer, and inflammation; veterinary preparations for administration by injection for the treatment of pain, itch, diabetes, cancer, and inflammation; veterinary preparations for immunisation against disease; veterinary preparations for use in improving the skin; veterinary preparations for use in treating the coat; veterinary preparations in dosage forms for veterinary use for the treatment of pain, itch, diabetes, cancer, and inflammation; veterinary products, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues; veterinary products for equines, namely, fully equinized monoclonal antibodies, equine fusion proteins; veterinary vaccines; biological preparations for veterinary purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; antibodies for pain, itch, diabetes, cancer, and inflammation; immunological antibodies for medical use for the treatment of cancer; monoclonal antibodies for medical diagnostic use; monoclonal antibodies for medical use for pain, itch, diabetes, cancer, and inflammation; monoclonal antibodies for therapeutic purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; products containing antibodies for use in medicine for pain, itch, diabetes, cancer, and inflammation; reagents for use in the development of monoclonal antibodies for medical diagnostic purposes; monoclonal antibodies for medical use for diagnostic purposes for pain, itch, diabetes, cancer and inflammation; biological preparations for medical purposes for the treatment of pain, itch, diabetes, cancer, and inflammation; biological products for medical use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation; biological reagents for medical diagnostic purposes for use in molecular biology; biological substances for medical use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation; reagents for use in biological processing for medical diagnostic purposes; reagents for use in biological processing for medical diagnostic purposes for veterinary purposes; therapeutic biological products, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation; monoclonal antibody reagents for medical diagnostic use; medical therapeutic agents for the treatment of pain, itch, diabetes, cancer, and inflammation; medical therapeutic drugs for the treatment of pain, itch, diabetes, cancer, and inflammation; animal care products for veterinary use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues or recombinant proteins for the treatment of pain, itch, diabetes, cancer, and inflammation; biotechnological preparations for veterinary use, namely, 100% species-specific monoclonal antibodies, canine or feline fusion proteins, and canine or feline insulin analogues for the treatment of pain, itch, diabetes, cancer, and inflammation | SECTION 71 - CANCELLED | — |
| 042 | Pharmaceutical research services; research relating to pharmaceuticals; services for assessing the efficiency of pharmaceuticals, namely, molecular binding, stability, immunogenicity and potency assays; services for assessing the safety of pharmaceuticals, namely, animal model and in-species clinical studies; services for assessing the efficiency of veterinary drugs, namely, molecular binding, stability, immunogenicity and potency assays and proof-of-concept and field studies; veterinary laboratory services; advisory services relating to scientific research, namely, advice in the field of therapeutic biologic drug candidate selection and development; laboratory services, namely, laboratory services for scientific research services and analysis of therapeutic biologic drugs; scientific laboratory services; scientific research; scientific research in the field of pharmacy; biological research; services for assessing the safety of veterinary drugs, namely, animal model and in-species clinical studies; provision of information relating to scientific research, namely, information on the identification and development of therapeutic biologic drug candidates | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NVIP Pty Ltd
- Other trademarks owned by NVIP Pty Ltd
- Other trademarks owned by NVIP Pty Ltd
- Other trademarks owned by NEXVET AUSTRALIA PTY LTD
- Other trademarks owned by Zoetis Services LLC
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named PETIZATION
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 14, 2025 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Mar 14, 2025 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Dec 31, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Oct 20, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 22, 2023 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| May 1, 2023 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Apr 30, 2023 | INPC | INVALIDATION PROCESSED | — |
| Mar 22, 2023 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Jul 22, 2022 | C71T | CANCELLED SECTION 71 | — |
| Sep 24, 2021 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Jan 5, 2021 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jan 2, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Dec 30, 2016 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Jul 8, 2016 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 7, 2016 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 7, 2016 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 5, 2016 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 5, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 20, 2015 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 20, 2015 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 17, 2015 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 30, 2015 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 30, 2015 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 30, 2015 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 16, 2015 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Sep 14, 2015 | ALIE | ASSIGNED TO LIE | — |
| Aug 20, 2015 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 18, 2015 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 18, 2015 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 18, 2015 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 13, 2015 | RFNP | REFUSAL PROCESSED BY IB | — |
| Feb 27, 2015 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 26, 2015 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 26, 2015 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 26, 2015 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 25, 2015 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 23, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 23, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 20, 2015 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |